Shots:

• The conditional approval is based on the P-II L-MIND study evaluating the safety and efficacy of tafasitamab + lenalidomide in patients with r/r DLBCL who are not eligible for ASCT
• Results: ORR (56.8%); CR rate (39.5%); PR rate (17.3%) as assessed by an IRC; m-DoR (43.9mos.) after a minimum follow up of 35mos.
• Tafasitamab is a humanized Fc-modified cytolytic CD19 targeting mAb & is co-marketed by both companies under the brand name Monjuvi in the US & Minjuvi in the EU. Additionally- both companies share global development rights for the therapy

| Ref: Incyte | Image: Morphosys US